Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14836154 | 0.80 | ALDH1A1 (0.54) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL4049279 | 0.79 | MEN1 (0.56) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL10440427 | 0.78 | LMNA (0.51) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL4146932 | 0.78 | NPSR1 (0.57) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14836137 | 0.78 | ALDH1A1 (0.51) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL20159187 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL19601190 | 0.77 | GSK3B (0.48) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL2705331 | 0.77 | MEN1 (0.52) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL19601213 | 0.76 | MAPT (0.55) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL4427268 | 0.76 | ALDH1A1 (0.44) | MEN1KMT2ASLC6A2SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180148438-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2018-05-31 | — | — | US | disclosed |
| US-20150158853-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2015-06-11 | — | — | US | disclosed |
| US-8865752-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140018401-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2014-01-16 | — | — | US | disclosed |
| US-8513291-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130102643-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP | 2013-04-25 | — | — | US | disclosed |
| EP-2576544-A2 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | Angion Biomedica Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153192-A2 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | MEN1 4799/4885KMT2A 4039/4885SLC6A2 4074/4885 |
| US-20180148438-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | MEN1 4799/4885KMT2A 4039/4885SLC6A2 4074/4885 |
| US-20150158853-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | MEN1 4799/4885KMT2A 4039/4885SLC6A2 4074/4885 |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | CYP7A1, CYP2E1, CYP11B1 | MEN1 4799/4885KMT2A 4039/4885SLC6A2 4074/4885 |
| US-20140018401-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | MEN1 4799/4885KMT2A 4039/4885SLC6A2 4074/4885 |
| US-20130102643-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | MEN1 4799/4885KMT2A 4039/4885SLC6A2 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.